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Summary
Objective: Glucocorticoid treatment of children often leads to growth retardation, and the precise target(s) in the growth plate responsible for
this effect are unknown. Angiogenesis is an important part of the endochondral ossification process, and VEGF expressed in the growth plate
is essential for proper angiogenesis to occur. Since glucocorticoid treatment down-regulates VEGF expression in cultured chondrocytes, we
hypothesized that in vivo glucocorticoid treatment could result in VEGF down-regulation in the growth plate and disturbed angiogenesis, thus
contributing to the growth retardation.
Design: We treated 6-week-old prepubertal piglets (10 kg) for 5 days with prednisolone (50 mg/day). Tibial growth plate sections were
studied for apoptosis and the expression of VEGF protein and mRNA and MMP-9 protein. Capillaries in the metaphysis were visualized by
CD31 immunostaining. Growth plate morphology (width of various zones) was determined by interactive measurements on hematoxylin/
eosin stained sections and apoptotic cells were detected by TUNEL assay.
Results: In the prednisolone-treated animals, the total width of the growth plate decreased to 81% of controls (P<0.02), which was explained
by a decrease of the width of the proliferative zone to 73% (P<0.05). The treatment had no effect on the orderly organization of the
chondrocyte columns. In the growth plates of control animals, apoptosis was shown in 5.8% of the hypertrophic chondrocytes and was
limited to the terminal hypertrophic chondrocytes. In prednisolone-treated animals, 40.5% of the hypertrophic chondrocytes was apoptotic
(P<0.02), with apoptotic chondrocytes also appearing higher in the hypertrophic zone.
We observed fewer capillaries and loss of their parallel organization in the metaphysis in the prednisolone-treated animals. The capillaries
were shorter and chaotic in appearance. In contrast to controls, in prednisolone-treated animals VEGF mRNA and protein could not be
detected in the hypertrophic zone of the growth plate. Trabecular bone length in the primary spongiosa was also diminished by the treatment.
No changes were observed in the expression pattern of MMP-9, a matrix metalloproteinase, which is also important for angiogenesis and
bone formation.
Conclusions: These results indicate that short-term glucocorticoid treatment of growing piglets severely disturbs the width of the growth plate,
apoptosis of chondrocytes, VEGF expression by hypertrophic chondrocytes, the normal invasion of blood vessels from the metaphysis to the
growth plate and bone formation at the chondro-osseous junction. These effects could alter the dynamics of endochondral ossification and
thus contribute to glucocorticoid-induced growth retardation.
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Introduction
Endochondral bone formation and longitudinal bone growth
are the result of proliferation, differentiation, maturation and
eventually apoptosis of chondrocytes within the growth
plate1. Apoptosis of terminal hypertrophic chondrocytes
(i.e., adjacent to the ossification front)2–4 is associated with
extracellular matrix degradation and vascular invasion of
the growth plate1. It results in a cartilaginous scaffold on
which new bone will be formed by invading osteoblasts. To
allow osteoblasts to invade the growth plate, vascular-
ization (i.e., angiogenesis) at the chondro-osseous junction
between metaphyseal bone and the growth plate is
required5. The growth plate secretes factors, which pro-
mote angiogenesis, including vascular endothelial growth
factor (VEGF)6,7. VEGF inactivation in mice results in
suppression of blood vessel invasion, impaired bone for-
mation and expansion of the hypertrophic zone of the
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growth plate, demonstrating that VEGF is essential for
attraction of capillaries to the growth plate and for growth
plate function6. Matrix metalloproteinases (MMPs) are
among the other factors, which are important for angio-
genesis and bone formation. They degrade the cartilage
extracellular matrix and release angiogenic factors such as
VEGF from the growth plate matrix8,9. In MMP-9 knock-out
mice, abnormal vascularization of the growth plate, delayed
apoptosis of hypertrophic chondrocytes and expansion of
the hypertrophic zone are observed10. The growth plates
of these mice show similar abnormalities as the growth
plates of mice in which VEGF is inactivated6. These
results suggest a link between cartilage matrix degradation,
apoptosis, angiogenesis, and VEGF and MMP-9
expression.
Agents that disturb longitudinal growth could potentially
act through interference with apoptosis and angiogenesis.
Glucocorticoids are effective drugs in anti-inflammatory and
immuno-suppressive therapy, but are well known to result
in growth retardation in children11,12 and in experimental
animal models13–17. Glucocorticoids act locally to inhibit
longitudinal bone growth, suggesting a mechanism intrinsic
to the growth plate4,18. Treatment of rats with glucocorti-
coids resulted in an increase of apoptosis of hypertrophic
chondrocytes4,19, indicating that glucocorticoids can inter-
fere with apoptosis in the growth plate. We have previously
shown that glucocorticoid treatment of cultured porcine
growth plate chondrocytes resulted in a down-regulation of
VEGF expression20. Given the pivotal role of growth plate-
derived VEGF in vascularization, it is conceivable that, in
addition to increasing apoptosis, glucocorticoids could tar-
get vascularization of the growth plate. Although a 30%
decrease in VEGF mRNA expression in the growth plate
was reported as a result of glucocorticoid treatment
in rats19, the effects on the actual vascular bed in the
metaphysis are unknown.
The growing piglet is a good model for growing chil-
dren21. When compared to the growth plates of rodents,
the pig growth plate more closely resembles the human
growth plate in terms of cellular numbers in the different
zones, cell kinetics and patterns of closure22,23. In this
model, we aimed to study the effects of a short-term (5
days) glucocorticoid treatment on a combination of factors,
which could influence growth. These include architecture
of the growth plate, apoptosis, VEGF expression and
angiogenesis.
Methods
ANIMAL STUDIES
Twelve 6-week-old (prepubertal) female cross-bred
(Landrace×Yorkshire) piglets24 with an average weight of
10 kg were studied. The animals were fed 50 g/kg per
day of a standard diet (De Heus Brokking Koudijs BV,
Barneveld, NL). One group of six piglets received 5 mg/kg
bodyweight prednisolone daily (orally), for a period of 5
days. The average weight gains of the groups did not differ
significantly from each other (0.89±0.35 kg for the con-
trol group and 0.75±0.45 kg for the prednisolone group).
Piglets were terminated at the end of the experiment by
injection of 1 g pentothal. The experimental protocol was
approved by the committee for Animal Experiments of the
University Medical Center Utrecht, The Netherlands.
TISSUE PREPARATION
Tibiae were dissected and the proximal heads were cut
sagitally and fixed in buffered 3.8% formalin for 3–6 days.
They were subsequently decalcified in 0.45 M phosphate-
buffered EDTA, pH 8.0 for 18–25 days, washed in PBS,
dehydrated through a series of ethanol and embedded in
paraffin. Sections of 10 µm were cut on an ultramicro-
tome and mounted on 2% amino-propyl-triethoxy silane
(APES)/3% glutaraldehyde coated glass slides. Sections
were dewaxed and hydrated prior to histochemical
analyses (see below).
MORPHOMETRY
Growth plate sections were stained with hematoxylin and
eosin and pictures of the growth plate sections were taken
with the Zeiss Axiomat HRC camera equipped with the Axio
Vision software, version 3.0. The interactive measurement
module was used for measurements of the growth plate
width. Total width of the growth plate (distance between the
epiphysis and the chondro-osseous junction) was deter-
mined from four images (magnification 50 times) per
growth plate section, covering the entire transverse area
within about 500 µm of the cortex. Of these images,
measurements at 200 µm intervals were performed (about
50 measurements per growth plate) and averaged. The
measuring lines were subsequently shortened to the first
appearance of regular chondrocyte columns (the boundary
between the resting and the proliferative zones) and to
the first enlargement of the flattened cells (the boundary
between the proliferative and the hypertrophic zones).
From the lengths of these lines the widths of the three
different zones of the growth plate were calculated.
IN SITU HYBRIDIZATION FOR VEGF
cDNA encoding human VEGF was kindly provided by Dr
M.F. Gebbink and Dr E.E. Voest (University Medical Center
Utrecht, the Netherlands)25 and was used as a template for
the synthesis of antisense and sense digoxigenin-labeled
cRNA probes. Standard RNA synthesis reactions using T7-
or T3-RNA polymerase were carried out using digoxigenin-
UTP (Roche, Mannheim, Germany) as a substrate26.
The in situ hybridization was performed as described
previously27. As a control for specific hybridization, sections
were hybridized with the appropriate sense probes, which
showed no signals.
IMMUNOHISTOCHEMISTRY
Endogenous peroxidase in sections was blocked by a
20 min incubation in 0.3% H2O2 in methanol. Antigen
retrieval was performed by heating at 90°C for 3 min in
10 mM Na-citrate, pH 6.0. Sections were blocked with
10% serum (Vector Laboratories, Inc., Burlingame, CA)
from the species in which the secondary antibody was
raised. The following primary antibodies directed against
human proteins were used: rabbit anti-VEGF, goat anti-
CD31/PECAM-1 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA) and goat anti-MMP-9 (R&D Systems, Inc.,
Minneapolis, MN). A blocking peptide for VEGF was from
Santa Cruz Biotechnology. Antibodies were used at 1:100
dilution in 1.5% blocking serum in PBS and incubated for
1 h at room temperature. For negative controls, the first
antibody was omitted from this diluent and for VEGF a
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blocking peptide was also used. Negative controls did not
show any signal. Biotinylated secondary antibodies (Vector
Laboratories) were used at 1:200 dilution and incubated for
30 min. For detection, the avidin–biotin peroxidase com-
plex method (Vector Laboratories Vectastain ABC kit) in
combination with nickel-enhanced 3,3′-diaminobenzidine
tetrahydrochloride (DAB; Sigma Chemical Co., St. Louis,
MO) as substrate was used. Sections were counterstained
with nuclear fast red, dehydrated and mounted with DPX
(Klinipath, Duiven, NL).
DETERMINATION OF APOPTOSIS
Apoptotic death was determined by the TdT-mediated
dUTP nick-end labeling (TUNEL) reaction (Promega,
Leiden, NL), which was performed according to the pro-
cedures of the manufacturer. For negative controls, the TdT
enzyme was replaced by water, which resulted in the
absence of any signal. After the DAB staining, sections
were counterstained with 0.1% light green, dehydrated and
mounted with DPX.
For quantitative evaluation of the number of TUNEL-
positive chondrocytes in the hypertrophic zone, sections
were coded and the number of positive cells in the hyper-
trophic zone were counted and expressed relative to the
total number of cells in the hypertrophic zone by two
independent observers.
STATISTICAL ANALYSIS
Results from the TUNEL staining and growth plate width
are expressed as mean±S.E.M. Statistical differences
between the control and the prednisolone-treated group
were determined by the unpaired t-test, using InStat
version 3.00 (GraphPad Software, Inc., San Diego, CA). A
P-value of <0.05 was considered statistically significant.
Results
GROWTH PLATE MORPHOLOGY
A 5-day prednisolone treatment (50 mg/day) of pre-
pubertal piglets significantly decreased the total width of
the proximal tibial growth plate to 81±6% of control values
(P<0.02) [Fig. 1(A and B)], caused by a significant
decrease of the proliferative zone to 73±9% of control
values (P<0.05) [Fig. 1(C)]. The hypertrophic zone showed
a small, non-significant decrease, whereas the resting zone
was not affected by the prednisolone treatment. The pred-
nisolone treatment had no effect on the morphology of the
growth plate, the chondrocytes being organized in the
same orderly columns as in the control animals [Fig. 1(A
and B)].
Trabecular bone length in the primary spongiosa of the
prednisolone-treated piglets was clearly diminished when
compared to the untreated controls [Fig. 1(D and E)]. At the
chondro-osseous junction, many of the calcified longitudi-
nal septae of the growth plate did not continue as bone
trabeculae, but were in direct contact with the marrow
cavity.
In the growth plates of the untreated piglets, only the
row of terminal hypertrophic chondrocytes contained a
low percentage (5.8±1.7%) of apoptotic cells [Fig. 1(F)].
Prednisolone treatment significantly increased the number
of apoptotic chondrocytes in the hypertrophic zone to
40.5±5.4% (6.9-fold increase, P<0.02) [Fig. 1(G)]. In
addition to the terminal hypertrophic zone, the higher
layers of the hypertrophic zone also contained apop-
totic chondrocytes in the prednisolone-treated piglets
[Fig. 1(G)].
ANGIOGENESIS
Immunohistochemistry for CD31/PECAM-1, a transmem-
brane glycoprotein in endothelial cells, was used to detect
capillaries. In the control piglets, metaphyseal blood
vessels ran parallel to the chondrocyte columns in the
growth plate and ended at the osteochondral junction [Fig.
2(A)]. Prednisolone treatment resulted in fewer, disorgan-
ized and short blood vessels, although they still penetrated
the hypertrophic zone of the growth plate [Fig. 2(B)]. We
studied whether this disturbed angiogenesis could be
due to changes in expression of VEGF and/or MMP-9
protein. In situ hybridization analysis showed predominant
expression of VEGF mRNA in the hypertrophic zone and in
occasional chondrocytes of the proliferative and resting
zones [Fig. 2(C)]. Immunohistochemistry showed a similar
expression pattern for the VEGF protein [Fig. 2(E)]. In the
prednisolone-treated piglets, VEGF mRNA and protein in
the hypertrophic zone were not detectable. In the osteo-
blasts aligning the trabeculae, the levels of VEGF mRNA
and protein did not appear to be affected by the pred-
nisolone treatment [Fig. 2(D and F)]. In control animals,
MMP-9 protein was detected in cells (most likely osteo-
clasts and osteoclast-like cells10) aligning the bone
trabeculae and at the transverse septae of the cartilage–
bone junction [Fig. 2(G)]. Prednisolone treatment did not
alter this expression pattern [Fig. 2(H)].
Discussion
In our study, piglets treated with glucocorticoids showed
(i) diminished proliferative zone and total growth plate
widths, (ii) changes in the morphology of the trabecular
bone in the primary spongiosa, (iii) increased apoptosis
in hypertrophic chondrocytes and (iv) decreased VEGF
expression in the growth plate and disturbed blood vessel
arrangement, but no changes in MMP-9. These changes
likely contribute to the growth retardation frequently
observed in children receiving glucocorticoid treat-
ment11,12. Although rodents and chickens can be used
as animal models for glucocorticoid-induced growth
retardation13–15, piglets are a better model for growing
children21 and their growth plates more closely resemble
the human growth plate22,23. Some of the present findings
have been reported before by us13,27,28 and others4,19,29,
but never before have the effects of glucocorticoids on the
morphology, apoptosis and angiogenesis of the piglet
growth plate been studied in an integrated approach.
The width of the proliferative zone in the piglet tibial
growth plate was reduced by 27% due to the glucocorticoid
treatment. We found a similar reduction of the proliferative
zone after a 1-week treatment of mice with dexametha-
sone28, and a 10% decrease in the proliferative zone,
concomitant with dexamethasone-induced growth inhibi-
tion, after 4 weeks of treatment13,27. In rats, glucocorticoid
treatment suppressed the proliferation rate without chang-
ing the width of this zone19,29, while in rabbits, dexametha-
sone decreased bone growth together with the width of the
proliferative zone30. In addition to these in vivo data, also
in vitro experiments using cultured rodent and porcine
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chondrocytes have shown that glucocorticoids inhibit their
proliferation31–34.
In addition to the proliferative zone, the hypertrophic
zone was also affected by the glucocorticoid treatment:
there was a sevenfold increase in apoptosis in the
prednisolone-treated piglets, with apoptotic chondrocytes
also appearing higher in the hypertrophic zone. In rats,
glucocorticoid treatment resulted in a twofold increase in
apoptosis of hypertrophic chondrocytes, but it remained
limited to the terminal hypertrophic chondrocytes4,19. It
is possible that these differences are due to different
susceptibilities of growth plates between species, or due
to differences in age and duration of the glucocorticoid
treatment. Interestingly, cell death of terminal chondrocytes
has been found to inversely correlate with the growth rate
of the bone35. Glucocorticoids, by increasing apoptosis,
thus may negatively regulate bone growth. In our study,
the width of the hypertrophic zone was only marginally
decreased. Possibly, an accelerated differentiation of pro-
liferative chondrocytes into hypertrophic chondrocytes36
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Fig. 1. Hematoxylin and eosin staining of representative sections of proximal tibial growth plates of 6-week-old prepubertal control (A, D) and
prednisolone (PRDL)-treated piglets (B, E). (C) Result of measurements of total growth plate width of control and prednisolone-treated
piglets and of the three different zones of the growth plate. The data represent the mean±S.E.M. *P<0.05, **P<0.02, PRDL relative to control.
Bars represent 500 µm in (A, B) and 200 µm in (D, E). T, denotes the total growth plate; R, resting zone; P, proliferative zone; H, hypertrophic
zone. (F, G) Apoptosis, as shown by TUNEL staining, in representative sections of tibial growth plates. (F) Control piglets; and (G)
prednisolone-treated piglets; TUNEL staining is shown as a dark precipitate. Arrows indicate examples of TUNEL-positive cells. The scale
bar represents 50 µm.
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Fig. 2. Angiogenesis in representative sections of tibial growth plates of control (A, C, E, G) and prednisolone (PRDL)-treated piglets (B, D,
F, H). (A, B) CD31 immunohistochemistry for detection of blood capillaries; (C, D) VEGF mRNA expression, as analyzed by in situ
hybridization; (E, F) VEGF protein expression, as analyzed by immunohistochemistry; (G, H) MMP-9 protein expression, as analyzed by
immunohistochemistry. The mRNA signal is shown as a blue precipitate and the protein signal as a dark precipitate. Scale bars represent
100 µm.
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compensates for the enhanced apoptosis, leaving the
number of chondrocytes in the hypertrophic zone
almost unchanged. Glucocorticoid-induced apoptosis could
involve the Bcl-2 protein family, the balance between Bcl-2
(anti-apoptotic) and Bax (pro-apoptotic) supposedly deter-
mining the rate of apoptosis37. However, prednisolone
treatment of our piglets did not show an effect on the
expression patterns of Bcl-2 and Bax (data not shown). In
previous studies, the ratio Bcl-2 to Bax could only partly
explain the increased apoptosis in the growth plate due to
glucocorticoid treatment19,38, suggesting that the occur-
rence of apoptosis is not directly related to detection of
altered Bax and Bcl-2 protein levels.
Besides the effects of the prednisolone treatment on
growth plate cartilage, the structure of primary trabeculae
and trabecular bone formation of the primary spongiosa
were also severely disturbed, already after this short-term
glucocorticoid treatment. Glucocorticoids have been shown
to affect bone formation in the secondary spongiosa by
decreasing bone formation and increasing bone resorp-
tion39,40, while increasing apoptosis of bone cells4,40,41.
Our study demonstrates that the primary spongiosa is
affected as well.
The severe defect in formation and organization of the
metaphyseal blood vessels in the tibia is perhaps the most
striking finding of this study. Although changes in the
growth plate apoptosis and VEGF gene expression (see
below) probably are the key factors behind this defect, also
the loss of trabecular architecture and direct effects of
glucocorticoids on endothelial cells could play a role in the
disturbed angiogenesis. In any event, normal blood vessel
invasion of the growth plate is required for endochondral
ossification and longitudinal bone growth1,5, as was dem-
onstrated by the delay in apoptosis and expansion of the
hypertrophic zone, which followed the impaired vascular
invasion resulting from inactivation of VEGF6. A reduced
bone regional blood flow was reported in pigs, which had
been treated with high-dose methylprednisolone for 2
weeks42. Since especially the epiphysis of the femur head
was affected, this could be an important pathogenetic factor
in glucocorticoid-induced osteonecrosis in this region.
Many genes have been described to be involved in
angiogenesis, with VEGF being one of the main modu-
lators5. In our control piglets, VEGF mRNA and protein are
predominantly expressed in the hypertrophic zone, which is
in accordance with other studies6,7. In the prednisolone-
treated animals, VEGF mRNA and protein were no longer
detectable in the hypertrophic zone. In prepubertal rats,
glucocorticoid treatment also resulted in a down-regulation
of VEGF in the growth plate19, although this decrease was
not as severe as shown in our piglets. We have previously
shown a down-regulation of VEGF expression by glucocor-
ticoids in piglet chondrocytes in vitro20. The importance of
growth plate-derived signals in the induction of capillary
ingrowth was elegantly described by Abad et al.43, who
excised, inverted and reimplanted rabbit growth plates. The
epiphyseal bone, which became adjacent to the hyper-
trophic zone of the growth plate, became the site of blood
vessel invasion. Although in that study the involvement of
VEGF was not directly addressed, our results, together with
the sequestration of VEGF leading to impaired vascular
invasion6, strongly suggest that down-regulation of VEGF
by glucocorticoids is directly responsible for the disturbed
angiogenesis, resulting in the observed defects in capillary
architecture. In this context, also the role of MMP-9 is
important, because it degrades the matrix and makes
VEGF bioavailable8,9. We found no effect of the glucocor-
ticoid treatment on the MMP-9 expression pattern. In a
variety of experimental models, glucocorticoids did inhibit
cytokine-induced expression of MMP-9 by interfering with
expression and/or binding of transcription factors AP-1,
NFB and Ets44,45. The actions of glucocorticoids on gene
expression could depend on the type of cell and/or its
location, as exemplified by the strong inhibition of VEGF
expression in the growth plate, without an apparent inhibi-
tion in the metaphysis. Although MMP-9 expression has
been reported in the hypertrophic zone of the growth
plate46, we did not detect it there. Rather, the pattern of
expression is in accordance with its reported expression
by osteoclasts, chondroclasts and endothelial cells8,10.
It would be of interest, however, to characterize the
expression of MMP-9 and its regulation by glucocorticoids
in cultured growth plate chondrocytes20. In addition, other
MMPs, in particular MMP-13, may play a role in endo-
chondral ossification8,47 and would be worth investigating.
Interestingly, the glucocorticoid treatment did not result in
the rachitic type of enlargement of the growth plate as was
observed after disrupting VEGF signaling6 or MMP-9
expression10. In both these experimental models, as well
as in vitamin D receptor ablated mice48, the expansion of
the hypertrophic zone appears to be caused by a delayed
or decreased apoptosis. The glucocorticoid treatment, on
the other hand, resulted in increased apoptosis, which
could explain the loss of cartilage even in the absence of
proper endochondral ossification. Although it is difficult to
quantitatively compare the defects in vascularization
among the various animal models, it is possible that in the
glucocorticoid-treated piglets there is still sufficient vascular
invasion for the delivery of MMP-9-expressing osteoclasts
and subsequent induction of apoptosis. Indeed, MMP-9
has been suggested to cause chondrocyte apoptosis, in
addition to its functioning as an angiogenic signal10.
Still other factors could be postulated as intermediates in
glucocorticoid action. For instance, TGF- inhibits angio-
genesis49 and stimulates apoptosis50. IGF-I, on the other
hand, protects against glucocorticoid-induced apoptosis51,
stimulates production of VEGF in growth plate chondro-
cytes20 and is important for angiogenesis52. We have
previously suggested that IGF-I in the growth plate could
contribute to or counteract the adverse effects of glucocor-
ticoids on growth27. It is of interest that vitamin D upregu-
lates VEGF expression both in cultured chondrocytes and
in the hypertrophic zone of the growth plate in vivo47.
Together with an upregulation of MMP-9 at the chondro-
osseous junction, this results in enhanced vascular
invasion of the growth plate. Considering these findings,
and the use of vitamin D to treat glucocorticoid-induced
osteoporosis53, it will be of interest to study whether vitamin
D can prevent the changes which we have now described
in the growth plate.
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